Avastin "Superior To Standard Care" For Treating Wet AMD, Researchers Say

A cheap drug used to treat bowel cancer should also be prescribed to patients with a condition that leads to sight loss, say UK researchers. Researchers at three eye centres in London, Bristol and Cheltenham carried out a pilot study in 131 patients with wet AMD.

The drug firm, Roche, which markets Avastin, has not applied for the drug to be used for wet AMD.

Barbara McLaughlan, RNIB campaigns manager for eye health and social care, said patients should continue to be treated with Lucentis until "robust evidence" was available on the safety and effectiveness of Avastin.

Posted in: Avastin, Macular Degeneration